![]() ![]() With energy and enthusiasm the international community agreed to collaboratively work on the aim on development, quality assurance, implementation, and dissemination of core outcome sets in dermatology. Jochen Schmitt and Hywel Williams initiated the international, multidisciplinary Cochrane Skin Group Core Outcome Set Initiative (CS-COUSIN) in 2014. The mission is to develop, disseminate and implement Core Outcome Sets (COS) for clinical trials and routine care through the engagement of patients, clinical experts, methodologists, industry partners and other possible stakeholders. C3’s vision is the improved health of patients through robust assessment of interventions in dermatology, skin care and related areas. Utikal who will then close the celebrations with a talk entitled "From melanocytes to pluripotent stem cells".The Consortium for Harmonizing Outcomes Research in Dermatology (CHORD) and the CS-Core Outcome Set Initiative (CS-COUSIN) groups have formed a union that has brought together a global network of stakeholders engaged in core outcome set (COS) development for dermatologic conditions under one organizational structure known as C3: CHORD COUSIN Collaboration. Sergij Goerdt, Director of the University Hospital of Dermatology, Venerology and Allergology Mannheim will give a speech in praise of Dr. Svante Päabo, Director of the Max Planck Institute of Evolutionary Anthropology (Leipzig) will give a lecture on the "Origin of humans from the perspective of the Neanderthal valley". Karlheinz Sonntag, vice-rector of the University of Heidelberg. Utikal in the Great Hall of the Old University on 30 th April. The prize will be officially awarded to Dr. Hella Bühler (1910 - 2002), a dentist from Heidelberg who bequeathed her fortune to the University of Heidelberg in order to establish an annual prize honouring outstanding scientific achievements in cancer research. Utikal to focus his future research on clarifying the mechanism involved in the conversion of melanocytes into iPS and gaining new insights in the development of tumours. The Hella Bühler Prize, which is worth 100,000 euros, will enable Dr. The prize award ceremony took place in the Great Hall of the Old University © University of Heidelberg In addition, neither melanocytes nor melanoma cells required the administration of the Sox 2 transcription factor, something that is normally required when using skin fibroblasts. The same is true for a malignant melanoma mouse cell line. ![]() Utikal and his colleagues at the Harvard Medical School were able to show that mouse and human melanocytes could be converted into induced pluripotent stem cells in much higher quantities than was previously possible by using fibroblasts. iPS cells therefore have huge therapeutic potential.Īlthough it was previously possible to generate iPS cells from body cells, it was impossible to produce a high enough quantity. In addition, iPS cells have the decisive advantage that they can be withdrawn from the patients' own body cells, thereby preventing the danger of rejection once transplanted. Since iPS cells can be produced without needing to destroy the embryo, there are no ethical concerns and the scientists hope that these cells will be able to largely replace research involving embryonic stem cells and that they will be used as the basis for cell replacement therapies. Like embryonic stem cells, iPS cells have the ability to differentiate into practically all cell types and hence tissue. ![]() During a research stay in Konrad Hochedlinger's laboratory at the Harvard Stem Cell Institute in Boston, USA, Utikal and his colleagues discovered how induced pluripotent stem cells (iPS cells) could be successfully produced from melanocytes. Utikal to support his work on pluripotent stem cells. ![]() Jochen Utikal, dermatologist at the Mannheim Medical Faculty at the University of Heidelberg. The Hella Bühler Prize is now in its fifth year and is awarded to young researchers at the University of Heidelberg who have already attracted attention due to the outstanding scientific quality of their cancer research. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |